CRL vs. RVTY: Charles River Laboratories vs. Revvity Stock Comparison
How do Charles River Laboratories (CRL) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Charles River Laboratories (CRL) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | CRL | RVTY |
|---|---|---|
| Name | Charles River Laboratories International, Inc. | Revvity Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 16.17 billion USD | 17.31 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 23, 2000 | February 21, 1973 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CRL | RVTY |
|---|---|---|
| Total Return (1Y) | 110.83% | 76.75% |
| Total Return (3Y, Annualized) | 27.87% | 24.22% |
| Total Return (5Y, Annualized) | -1.57% | -1.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CRL | RVTY |
|---|---|---|
| Volatility (1Y, Annualized) | 47.81% | 40.22% |
| Beta (5Y) | 1.33 | 1.07 |
| Max Drawdown (5Y) | -74.73% | -59.01% |
| Avg. Volume (3M) | 1.05M | 1.89M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CRL | RVTY |
|---|---|---|
| Sharpe Ratio (1Y) | 2.23 | 1.80 |
| Sortino Ratio (1Y) | 3.58 | 2.90 |
Profitability
ROE (TTM)
Both Charles River Laboratories (CRL) at 1.27% and Revvity (RVTY) at 3.45% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.27%
- Max
- 109.18%
- Q3
- 6.23%
- CRL
- 1.27%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.45%
- Max
- 109.18%
- Q3
- 6.23%
- RVTY
- 3.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Revvity (RVTY) at 8.61% retains a top-quartile share of revenue as profit, ahead of Charles River Laboratories (CRL) at 1.01%, which keeps about the industry-typical share.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01%
- Max
- 18.05%
- Q3
- 4.78%
- CRL
- 1.01%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.61%
- Max
- 18.05%
- RVTY
- 8.61%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Charles River Laboratories (CRL) at 23.42% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.42%
- Max
- 83.12%
- CRL
- 23.42%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.06%
- Max
- 83.12%
- RVTY
- 17.06%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | CRL | RVTY |
|---|---|---|
| ROE (TTM) | 1.27% | 3.45% |
| ROA (TTM) | 4.74% | 2.54% |
| Net Margin (TTM) | 1.01% | 8.61% |
| Operating Margin (TTM) | 23.42% | 17.06% |
| Gross Margin (TTM) | 35.10% | 55.91% |
Growth
Revenue Growth
Revvity (RVTY) at 3.67% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Revvity (RVTY) at -5.91% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.
Growth Metrics
| Metric | CRL | RVTY |
|---|---|---|
| Revenue Growth (YoY) | -0.85% | 3.67% |
| Revenue Growth (3Y CAGR) | 0.33% | -4.82% |
| EPS Growth (YoY) | -1,555.00% | -5.91% |
| EPS Growth (3Y CAGR) | -- | -23.26% |
Financial Strength
Current Ratio (MRQ)
Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.41
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- CRL
- 1.41
- Min
- 0.10
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.65
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- RVTY
- 2.65
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Revvity (RVTY) at 0.38 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 1.42
- CRL
- 0.87
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- RVTY
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CRL | RVTY |
|---|---|---|
| Current Ratio (MRQ) | 1.41 | 2.65 |
| Debt / Equity (MRQ) | 0.87 | 0.38 |
| Net Debt / EBITDA | 2.92 | 2.43 |
Dividends
Dividend Yield (TTM)
Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19%
- RVTY
- 0.19%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Charles River Laboratories (CRL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.40%
- RVTY
- 13.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CRL | RVTY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.19% |
| Dividend Payout Ratio (TTM) | 0.00% | 13.40% |
Valuation
P/E Ratio (TTM)
Both look expensive on trailing earnings: Revvity (RVTY) at 68.94 sits in the richer P/E ratio quartile, and Charles River Laboratories (CRL) at 366.87 is richer still, above its industry range.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
366.87
- CRL
- 366.87
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
68.94
- Max
- 85.34
- RVTY
- 68.94
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.07
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- CRL
- 4.07
- Q1
- 3.01
- Min
- 0.01
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.88
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- RVTY
- 5.88
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.01
- Max
- 13.53
- Q3
- 6.54
- CRL
- 5.01
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.39
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- RVTY
- 2.39
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | CRL | RVTY |
|---|---|---|
| P/E Ratio (TTM) | 366.87 | 68.94 |
| P/S Ratio (TTM) | 4.07 | 5.88 |
| P/B Ratio (MRQ) | 5.01 | 2.39 |
| Free Cash Flow Yield (TTM) | 2.74% | 3.62% |